2.09
-0.014(-0.67%)
Currency In USD
| Previous Close | 1.94 |
| Open | 1.99 |
| Day High | 2.15 |
| Day Low | 1.93 |
| 52-Week High | 19.63 |
| 52-Week Low | 1.93 |
| Volume | 33,851 |
| Average Volume | 812,510 |
| Market Cap | 4.76M |
| PE | -0.07 |
| EPS | -28.75 |
| Moving Average 50 Days | 3.41 |
| Moving Average 200 Days | 5.7 |
| Change | 0.16 |
If you invested $1000 in Processa Pharmaceuticals, Inc. (PCSA) 10 years ago, it would be worth $37.5 as of February 26, 2026 at a share price of $2.1. Whereas If you bought $1000 worth of Processa Pharmaceuticals, Inc. (PCSA) shares 5 years ago, it would be worth $9.19 as of February 26, 2026 at a share price of $2.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 12, 2026 2:15 PM GMT
VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that George Ng, Chief Executive Officer
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
GlobeNewswire Inc.
Jan 05, 2026 2:15 PM GMT
Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, t
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
GlobeNewswire Inc.
Dec 17, 2025 1:00 PM GMT
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct formal interim analysis in early 2026 VERO BEACH, Fla.,